Evaluation of Factors Associated with Platinum-sensitivity Status and Survival in Limited-stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 9

PMID 29113400

Citations 15

Authors

Qiang Wen

Xue Meng

Peng Xie

Shijiang Wang

Xindong Sun

Jinming Yu

Affiliations

Soon will be listed here.

Abstract

In this retrospective study, we analyzed the association of clinicopathological factors and therapeutic plans with platinum-sensitivity status and survival of limited-stage small cell lung cancer (LS-SCLC) patients. We enrolled 452 LS-SCLC patients with 279 platinum sensitive and 173 platinum refractory patients. The low serum neuro-specific enolase levels (NSE; = 0.011), neutrophil-to-lymphocyte ratios (NLR; = 0.013) and higher objective response rates ( = 0.003) were associated with sensitive group but not the refractory group. Multivariate analysis showed that treatment modality (HR = 0.267, < 0.001), serum lactate dehydrogenase (LDH; HR = 1.894, = 0.016), NLR (HR = 2.043, = 0.043) and platinum-sensitivity status (HR = 0.561, = 0.036) were independent prognostic factors for survival. We further showed that the numbers of chemotherapy cycles and response to first-line therapy were independent prognostic factors for refractory patients only. Our study demonstrates that platinum-sensitivity status is of prognostic importance, as it is strongly associated with survival in LS-SCLC patients.

Citing Articles

Predictive Value of Inflammatory Scores for Left Atrium Thrombosis in Ischemic Stroke Without Atrial Fibrillation.

Cicek V, Kilic S, Dogan S, Erdem A, Babaoglu M, Yilmaz I Medicina (Kaunas). 2025; 60(12.

PMID: 39768925 PMC: 11677452. DOI: 10.3390/medicina60122046.

The prognostic impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on patients with small cell lung cancer receiving first-line platinum-based chemotherapy: a systematic review and meta-analysis.

Zhao Y, Wang Y, Jiang Y, Yang J, Zhang Y BMC Pulm Med. 2024; 24(1):630.

PMID: 39710633 PMC: 11665107. DOI: 10.1186/s12890-024-03447-2.

Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.

Yu T, Hu X, Liufu W, Niu S, Lian H, Ma H Cancer Med. 2024; 13(8):e7215.

PMID: 38659392 PMC: 11043670. DOI: 10.1002/cam4.7215.

Serum lactate dehydrogenase predicts brain metastasis and survival in limited-stage small cell lung cancer patients treated with thoracic radiotherapy and prophylactic cranial irradiation.

Liu J, Wu D, Shen B, Chen M, Zhou X, Zhang P Strahlenther Onkol. 2022; 198(12):1094-1104.

PMID: 35857072 DOI: 10.1007/s00066-022-01977-4.

Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients.

Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B BMC Cancer. 2022; 22(1):63.

PMID: 35027001 PMC: 8759208. DOI: 10.1186/s12885-021-09108-5.

References

Lu H, Wang X, Mao W . Targeted therapies in small cell lung cancer. Oncol Lett. 2012; 5(1):3-11. PMC: 3525471. DOI: 10.3892/ol.2012.791. View

Yan H, Wang R, Jiang S, Zhu K, Feng R, Xu X . NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus. Med Oncol. 2013; 31(1):796. DOI: 10.1007/s12032-013-0796-0. View

Byhardt R, Hartz A, Libnoch J, Hansen R, Cox J . Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys. 1986; 12(5):771-7. DOI: 10.1016/0360-3016(86)90035-0. View

Tabuchi Y, Shinka S, Ishida H . The effects of anesthesia and surgery on count and function of neutrophils. J Anesth. 1989; 3(2):123-31. DOI: 10.1007/s0054090030123. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, Sudo A . The combined use of the neutrophil-lymphocyte ratio and C-reactive protein level as prognostic predictors in adult patients with soft tissue sarcoma. J Surg Oncol. 2013; 108(7):481-5. DOI: 10.1002/jso.23424. View

Fried D, Morris D, Poole C, Rosenman J, Halle J, Detterbeck F . Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22(23):4837-45. DOI: 10.1200/JCO.2004.01.178. View

Xu H, Kadlececk S, Profka H, Glickson J, Rizi R, Li L . Is higher lactate an indicator of tumor metastatic risk? A pilot MRS study using hyperpolarized (13)C-pyruvate. Acad Radiol. 2014; 21(2):223-31. PMC: 4169113. DOI: 10.1016/j.acra.2013.11.014. View

Owonikoko T, Behera M, Chen Z, Bhimani C, Curran W, Khuri F . A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012; 7(5):866-72. PMC: 3381878. DOI: 10.1097/JTO.0b013e31824c7f4b. View

10.

Albain K, Crowley J, LeBlanc M, Livingston R . Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990; 8(9):1563-74. DOI: 10.1200/JCO.1990.8.9.1563. View

11.

Johnson D, Greco F, Strupp J, Hande K, Hainsworth J . Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 1990; 8(10):1613-7. DOI: 10.1200/JCO.1990.8.10.1613. View

12.

Lally B, Geiger A, Urbanic J, Butler J, Wentworth S, Perry M . Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2008; 64(2):226-31. DOI: 10.1016/j.lungcan.2008.08.010. View

13.

Sun Z, Yang P . Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 2004; 5(3):182-90. DOI: 10.1016/S1470-2045(04)01414-7. View

14.

Bogart J, Herndon 2nd J, Lyss A, Watson D, Miller A, Lee M . 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004; 59(2):460-8. DOI: 10.1016/j.ijrobp.2003.10.021. View

15.

Bremnes R, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S . The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003; 39(3):303-13. DOI: 10.1016/s0169-5002(02)00508-1. View

16.

Ustuner Z, Saip P, Yasasever V, Vural B, Yazar A, Bal C . Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol. 2008; 25(4):394-9. DOI: 10.1007/s12032-008-9052-4. View

17.

Li J, Dai C, Chen P, Wu J, Bao Q, Qiu H . Survival and prognostic factors in small cell lung cancer. Med Oncol. 2009; 27(1):73-81. DOI: 10.1007/s12032-009-9174-3. View

18.

Kang M, Go S, Song H, Lee A, Kim S, Kang J . The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014; 111(3):452-60. PMC: 4119986. DOI: 10.1038/bjc.2014.317. View

19.

Chua W, Charles K, Baracos V, Clarke S . Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011; 104(8):1288-95. PMC: 3078587. DOI: 10.1038/bjc.2011.100. View

20.

Vincent M, Evans B, Smith I . First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol. 1988; 21(1):45-8. DOI: 10.1007/BF00262737. View